Research programme: anti-cancer peptides - Riptide BioscienceAlternative Names: RP-182
Latest Information Update: 07 Oct 2016
At a glance
- Originator Riptide Bioscience
- Developer National Cancer Institute (USA); Riptide Bioscience
- Class Peptides
- Mechanism of Action Macrophage inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Preclinical Cancer; Pancreatic cancer